

Press release from Emotra AB (publ)

Göteborg, January 21, 2016

## Emotra granted financial support from the EU Horizon 2020

**Emotra AB announces that the Company has been granted financial support from the EU Horizon 2020 programme. The application, submitted in December 2015, is for a €50K grant to finance a phase 1 feasibility study to demonstrate the potential to broaden the EDOR indication range to include children and young people up to 20 years of age. The feasibility study will also include a review of the conditions to develop “EDOR Interconnect”, a global communication platform that will facilitate Emotra’s communication with clinical departments and serve them in different parts of the world.**

The aim of the feasibility study is to prove that Emotra has the potential to implement a clinical multi-centre study showing that EDOR works when assessing the suicide risk in the target group composed of children and young people up to the age of 20 and that there is a large market for this kind of method. The aim is also to demonstrate the utility of “EDOR Interconnect”, a global communication platform, which will facilitate the use of EDOR. It is intended to be used for internet-based communication between clinics in different parts of the world and for Emotra’s analytical activities. The idea is that EDOR Interconnect will also include a database in which all patients and test data will be stored. The database will make it possible to check the reliability of the method and to facilitate further research on what the suicide risks look like in different populations.

Broadening the indication range for EDOR to younger people and developing EDOR Interconnect have long-term strategic importance for Emotra. The first activity is aimed at a significant increase in the future market for EDOR. The second one would mean significantly strengthening customer relations. The feasibility study may take a maximum of 6 months and if it shows good potential, an application for a full phase 2 study will be submitted. The EU can finance a phase 2 study with up to €2.5M.

### **For further information about the Company, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)